Page last updated: 2024-11-05

biuret

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Biuret: Used as feed supplement for sheep and cattle since it is a good non-protein nitrogen source. In strongly alkaline solution biuret gives a violet color with copper sulfate. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

biuret : A member of the class of condensed ureas that is the compound formed by the condensation of two molecules of urea; the parent compound of the biuret group of compounds. Used as a non-protein nitrogen source in ruminant feed. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7913
CHEMBL ID1889026
CHEBI ID18138
SCHEMBL ID15045
SCHEMBL ID8045576
MeSH IDM0002621

Synonyms (72)

Synonym
ureidoformamide
l-101
allophanamide
nsc8020
isobiuret
dicarbamylamine
carbamylurea
allophanic acid amide
urea, (aminocarbonyl)-
nsc-8020
allophanimidic acid
imidodicarbonic diamide
2-imidodicarbonic diamide
(aminocarbonyl)urea
CHEBI:18138 ,
dicarbonimidic diamide
allophanimidic acid (van)
caswell no. 106a
ai3-14905
epa pesticide chemical code 206200
nsc 8020
hsdb 5382
caswell no. 159a
einecs 203-559-0
isobiuret (van)
carbamoylurea
NCGC00091696-01
C06555
108-19-0
biuret
biuret (carbamylurea; imidodicarbonic diamide)
STK068927
B3228
B0513
AKOS000491582
BMSE000470
NCGC00091696-02
unii-89lj369d1h
89lj369d1h ,
dtxsid2026783 ,
dtxcid606783
NCGC00257088-01
cas-108-19-0
tox21_303191
NCGC00259712-01
tox21_202163
BBL012096
biuret reagent
FT-0623139
biuret [mi]
imidodicarbonic diamide [hsdb]
SCHEMBL15045
dicarbonimidic diamide #
SCHEMBL8045576
CHEMBL1889026
W-108725
mfcd00007946
biuret, 97%
allophanimidicacid
CS-W016643
biuret, for synthesis, 97.0%
biuret, vetec(tm) reagent grade, 98%
1-(carbamoylamino)formamide
Q414902
DS-12122
c5j ,
D78197
A895347
i(1/4)-imido-dicarbonic acid diamide
EN300-352284
SY010569
Z57206006

Research Excerpts

Overview

Biuret deamination is an essential step in cyanuric acid mineralization. Biuret is a minor component of urea fertilizer and an intermediate in s-triazine herbicide biodegradation.

ExcerptReferenceRelevance
"Biuret deamination is an essential step in cyanuric acid mineralization. "( Structural and biochemical characterization of the biuret hydrolase (BiuH) from the cyanuric acid catabolism pathway of Rhizobium leguminasorum bv. viciae 3841.
Esquirol, L; French, NG; Hartley, CJ; Lucent, D; Newman, J; Peat, TS; Scott, C; Wilding, M, 2018
)
2.18
"Biuret is a minor component of urea fertilizer and an intermediate in s-triazine herbicide biodegradation. "( Microbial biodegradation of biuret: defining biuret hydrolases within the isochorismatase superfamily.
Badalamenti, JP; Dodge, AG; Robinson, SL; Tassoulas, LJ; Wackett, LP, 2018
)
2.22

Dosage Studied

ExcerptRelevanceReference
" No remarkable changes were investigated in findings at near-term caesarean section in any dosed group including 400 mg/kg/day."( [Reproduction study of 1,1,3-trimethyl-5-phenylbiuret (ST-281): teratological study in rabbits by oral administration].
Imamura, K; Kashihara, A; Koida, M; Morita, K; Shinomiya, M; Yamakita, O; Yoshida, R, 1986
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
condensed ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
cyanurate degradation49
superpathway of atrazine degradation718

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.25890.000214.376460.0339AID588532
Nuclear receptor ROR-gammaHomo sapiens (human)Potency66.82420.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (66.17)18.7374
1990's6 (4.51)18.2507
2000's12 (9.02)29.6817
2010's20 (15.04)24.3611
2020's7 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.29 (24.57)
Research Supply Index5.04 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index149.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other153 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]